We are updating the osteoporosis guideline to bring all NICE recommendations into one comprehensive resource. The revised guidance will be delivered in two parts:
Part 1: will cover identifying adults who should be assessed for fragility fracture risk, methods of risk assessment, identifying vertebral fractures, treatment criteria and repeat risk assessment (timing and methods) for people not receiving treatment.
Part 2: will cover risk assessment for people with a learning disability, treatment (pharmacological, exercise and calcium and vitamin D), monitoring of treatment and treatment pauses, incorporating recommendations from a new Multiple Technology Appraisal (MTA) to create a single set of pharmacological treatment guidelines.
The Stakeholder consultation on Part 1 and the consultation on the MTA scope runs from 13 January to 23 February 2026.
Draft guidance consultation
Draft guideline & MTA consultation
You can now review and comment on this draft guideline and MTA scope. Please provide your feedback using the respective comment forms because the draft guideline and the MTA scope are managed by different processes and overseen by separate project teams.
The consultation closes on 23 February 2026 at 5pm.
How to comment
- Register your organisation or comment as an individual
If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.
Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.
We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.
- Read the draft guideline consultation documents
Documents to comment on:
- Equality impact assessment
- Draft guideline
- Evidence reviews:
- Evidence review A: Risk factors for fragility fracture
- Evidence review B: Searching and analysis of electronic health records
- Evidence review C: Validity of fragility fracture risk prediction
- Evidence review D: Accuracy of bone assessment methods
- Evidence review E: Effectiveness of fragility fracture risk prediction tools
- Evidence review F: Diagnostic accuracy of Vfrac
- Evidence review G: Diagnosing vertebral fractures with DXA based VFA
- Evidence review H: Fracture risk monitoring in non-treatment group
Appendices:
- Methods Chapter
- Supporting documentation Osteoporosis CG146 Full Guideline
- Supporting documentation Osteoporosis CG146 Appendices
Other information about the consultation:
- Committee member list
- Committee Declarations of Interest register
- Developing NICE guidelines how to get involved
- Final scope
- Add your comments
- You must use this form: Guideline comments form - Please note: the draft guideline and the MTA scope are managed by different processes and overseen by different project groups.
- You must declare any links with, or funding from, the tobacco industry
If you share similar views with another organisation, send a joint response.
Make sure you consider:
- The areas that will have the biggest impact on practice and be challenging to implement
- How to help users overcome challenges
- Developing NICE guidelines: how to get involved suggests some other areas to comment on.
- Read the draft MTA scope consultation documents
Read the MTA scope consultation and proposal and comment using the MTA scope comments form:
5. Email the forms to us
Email: osteoporosis@nice.org.uk
Deadline: 23 February 2026 at 5pm
This page was last updated: